As M&A investments could hit $400 billion this year, watch for buys in health technology and data, biotech, pharma and medical devices.
The shares of the animal health company could be finding a bottom after losing substantial ground since the start of the year.
The stock of the maker of glucose monitoring systems may be seeking a bottom but it isn't clear whether it has gotten there yet.
Here's where traders could go long.
Here's how to approach CI after our Dec. 21 recommendation.
The hospital operator sports favorable technical signals going into the New Year.
Here's why down-and-out Medtronic could see a good year ahead.
Blue chip stock Bristol-Myers Squibb has a high dividend yield and an excellent pipeline.
We're setting new price targets for the health insurer as its technical signals remain largely bullish.
Pay attention when a stock does not decline on what is perceived as bearish news.